FDA Fraud Governance Prescription Drug Pricing 
Hall Render
MAY 10, 2024
Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass. Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass.
Drug & Device Law
OCTOBER 10, 2022
The manufacturer sought to cover Medicare patients’ Part D cost-sharing obligations for the drug – which were estimated at approximately $13,000 per year – but the OIG said “no thanks,” and the Second Circuit has affirmed that outcome. A little background is in order. ATTR-CM only affects about 150,000 Americans, who are mostly elderly.
Expert insights. Personalized for you.
40 
Let's personalize your content